Tirzepatide vs Semaglutide
Side-by-side comparison of Tirzepatide, Semaglutide — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Tirzepatide Tirzepatide (GIP/GLP-1 Dual Agonist) Weight Loss | Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss |
|---|---|---|
| Basics | ||
| Molecular type | Dual GIP/GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Amino acids | 39 | 31 |
| Molecular weight | 4,813.5 Da | 4,113.6 Da |
| Half-life | ~5 days | ~7 days |
| Route(s) | Subcutaneous injection | Subcutaneous injection, Oral (Rybelsus) |
| Mechanism & Research | ||
| Primary mechanism | Tirzepatide's dual mechanism differentiates it from pure GLP-1 agonists. The GIP component contributes additional appetite suppression via hypothalamic GIP receptors and improves insulin secretion efficiency. The two inc… | Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… |
| Research status | FDA Approved | FDA Approved |
| Evidence summary | Tirzepatide's clinical development programme (SURPASS for diabetes, SURMOUNT for obesity) has consistently demonstrated superior weight loss outcomes to comparator GLP-1 agonists. The SURMOUNT-1 trial set a new benchmark… | Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… |
| Protocol & Dosing | ||
| Typical dose | 2.5mg → 15mg weekly | 0.25mg → 2.4mg weekly (weight management) |
| Frequency | Once weekly | Once weekly |
| Duration | Ongoing (chronic) | Ongoing (chronic management) |
| Timing | Same day each week, any time of day | Same day each week, any time |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Not Prohibited |
| Deeper reading | ||
| Related peptides | Semaglutide, AOD-9604, Tesamorelin | Tirzepatide, AOD-9604, Tesamorelin |
| Full profile | Read full Tirzepatide profile → | Read full Semaglutide profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.